Latest Non Dilutive Funding News

Nexsen Limited teams with Universiti Malaya to launch a joint research facility aiming to develop a rapid biosensor detecting E. coli and Salmonella simultaneously, addressing a critical food safety gap in Southeast Asia.

GoldArc Resources has secured full ownership of Mt Stirling and launched partner-funded drilling campaigns across its Leonora North and South projects, delivering multiple high-grade gold results and locking in a binding development deal with Mineral Mining Services.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Chariot Resources advances its Nigerian lithium acquisition with six licences transferred and spodumene confirmed in samples, while raising A$2.15 million and securing a A$3.5 million loan refinancing.

Titomic Limited is gearing up for a strategic shift to the US with a planned redomicile in H2 2026, while clinching major contracts across aerospace, defense, and rail sectors and achieving critical certifications that underpin its manufacturing ambitions.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.

Algorae Pharmaceuticals strengthened its balance sheet with $5.47 million cash reserves and broadened its commercial footprint through new licensing deals and AI-driven drug validation.

Premier1 Lithium completed its maiden RC drilling at Yalgoo and confirmed expanded gold anomalies at Rochefort through advanced geophysical surveys, setting up follow-up drilling in 2026.

Latitude 66 has locked in exploration permits for its high-grade KSB gold-cobalt project in Finland following a key legislative amendment, while its Laverton drilling campaign in Western Australia continues to reveal promising gold mineralisation with potential for resource growth.

Talga Group reported record anode production at its EVA plant and significant progress on its 5,000tpa Vittangi anode plant FEED study, alongside strategic partnerships and exploration breakthroughs.

Actinogen Medical’s pivotal XanaMIA trial clears a key interim hurdle with the Data Monitoring Committee endorsing continuation, while a $16.8 million capital raise and non-dilutive funding bolster its balance sheet ahead of final results due November 2026.

Alicanto Minerals has kicked off a 50,000-metre drilling campaign to expand the 915,000oz Mt Henry gold resource, backed by a fresh $18.1 million non-dilutive funding package and key leadership changes.